Completed PHASE4 INTERVENTIONAL NCT00590629

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

Sponsor: Cedars-Sinai Medical Center

Interventions Niaspan

Updated 5 times since 2017 Last updated: Sep 13, 2011 Started: Jun 30, 2002 Primary completion: Nov 30, 2005 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by Cedars-Sinai Medical Center and has accumulated 5 data snapshots since 2002. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cedars-Sinai Medical Center
General Clinical Research Center (GCRC)
Kos Pharmaceuticals

Data source: Cedars-Sinai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States